Laurens Vyncke¹, Celia Bovijn¹, Ewald Pauwels², Tim Van Acker¹, Elien Ruyssinck¹, Jan Tavernier¹, Frank Peelman¹

¹VIB-Department of Medical Protein Research/UGhent, Ghent, Belgium; ²UGhent Center for Molecular Modeling, Ghent, Belgium

By combining the mammalian two-hybrid system MAPPIT and saturation mutagenesis, we complement and extend crystallographic and NMR data, and reveal how TIR domains interact. Our approach fully delineates the interaction sites on the MyD88 TIR domain for homo-oligomerization and for interaction with Mal and TLR4. Interactions between three sites drive MyD88 homo-oligomerization. The BB-loop interacts with the α E-helix, explaining how BB-loop mimetics inhibit MyD88 signaling. The α C'-helix interacts symmetrically. The MyD88 TIR domains thus assemble into a left-handed helix, compatible with the Myddosome death domain crystal structure. Our assembly explains regulation of MyD88 by Mal, phosphorylation, and oncogenic mutations. These findings provide a paradigm for the interaction of mammalian TIR domains.


Random mutagenesis and MAPPIT





UNIVERSITEIT

GENT



	Mal bait	MyD88 bait	
cyan	< 60%	≥ 75%	
blue	< 30%	≥ 75%	
magenta	< 60% ≥ 60% and < 75%		
orange < 60%		< 60%	
red	red < 30% < 30%		

MAPPIT is based on the JAK-STAT signaling pathway of class I cytokine receptors. Upon ligand binding, the leptin receptor complex is reorganized, leading to recruitment and cross-activation of associated Janus kinases (JAKs). The bait protein is fused to the mutated intracellular part of the leptin receptor, which is deficient for the recruitment of Signal Transducer and Activator of Transcription 3 (STAT3). The prey protein is tethered to a fragment of the gp130 receptor chain which harbours several STAT3 recruitment sites. Upon binding of prey and bait, STAT3 is phosphorylated and forms an activated STAT3 complex. This complex migrates to the nucleus, resulting in the induction of a STAT3-responsive reporter gene.

(a) The first binding site "I" (BS I) includes the residues of the BB-loop. Mutations at these positions strongly affect the interaction with MAL, MyD88 and TLR4. (b) A second binding site "II" (BS II) is found around the C-terminal half of the α C'-helix. Mutations at the center of this binding site affect the MyD88 TIR-MyD88 dimerization assay. (c) The third binding site "III" (BS III) is situated at the N-terminal half of the α E-helix. Similarly to BS I, mutations at this site strongly affect all testes interaction assays. A fourth site "IV" (BS IV) consists mostly of residues of the DE-loop and EE-loop. Mutations in this site more specifically affect the interaction with MAL and TLR4ic. Non-mutated residues are uncolored, and the backbone is indicated in black.

	Mal bait	MyD88 bait	NF-κB activation
yellow	≥ 60%	≥ 60%	< 70%
cyan	< 60%	≥ 60%	≥ 70%
magenta	< 60%	< 60%	< 60%
green	< 60%	≥ 60%	< 70%

(a, b, and c) Mutations in BS I, BS III, and in the center of BS II strongly reduce the NF-kB activation, corroborating the effect of these mutations on MyD88-MyD88 interaction. (c) Mutations in BS IV have no appreciable effect on the NF-κB reporter activation, in line with a specific role of this site in MyD88-MAL interaction. Nonmutated residues are uncolored, and the backbone is indicated in black.

